Fixed drug reactions are common. FDEs are so named because they recur at the same site with each exposure to the medication. The time from ingestion of the offending agent to the appearance of symptoms is between 30 minutes and 8 hours, averaging 2 hours. In most patients, six or fewer lesions occur, and often only one. Infrequently, FDEs may be multifocal with numerous lesions (generalized) and can blisters, termed generalized bullous fixed drug eruption (GBDFE), which can mimic SJS/TEN (Fig 6.27). They may present anywhere on the body, but half occur on the oral and genital mucosa. FDEs represent 2% of all genital ulcers evaluated at clinics for sexually transmitted diseases and can occur in young boys. In males, lesions are usually unifocal and can affect the glans or shaft of the penis. FDE of the vulva is often symmetric, presenting as an erosive vulvitis, with lesions on the labia minora and majora and extending to the perineum. Other unusual variants of FDE include eczematous, urticarial, papular, purpuric, linear, giant, and psoriasiform. At times, some lesions of FDE will not reactivate with exposure because of a presumed “refractory period” that may last from weeks to months.
Clinically, an FDE begins as a red round/oval patch that can develop a dusky, intensely inflamed central portion and resemble an iris or target esion similar to erythema multiforme, which may blister and erode. Lesions of the genital and oral mucosae usually present as erosions. Most lesions are 1 to several cm in diameter, but larger plaques may occur, mimicking cellulitis. Characteristically, prolonged or permanent postinflammatory hyperpigmentation results, although a nonpigmenting variant of an FDE is recognized. With repeated or continued ingestion of the offending medication, new lesions may be added, sometimes eventuating in a clinical picture similar to SJS with similar morbidity and mortality. Histologically, an interface dermatitis occurs with subepidermal vesicle formation, necrosis of keratinocytes, and a mixed superficial and deep infiltrate of neutrophils, eosinophils, and mononuclear cells. Pigment incontinence is usually marked, correlating with the pigmentation resulting from repeated FDEs at the same site. Because biopsies are generally performed during the acute stage of a recurrence, the stratum corneum is normal. Papillary dermal fibrosis and deep perivascular pigment incontinence are often present from prior episodes.
Medications inducing FDEs are usually those taken intermittently. Many of the NSAIDs, especially pyrazolone derivatives, paracetamol, naproxen, oxicams, and mefenamic acid, cause FDE, with a special predilection for the lips. Sulfonamides, trimethoprim, and TMP-SMX are now responsible for the majority of genital FDEs. Barbiturates, tetracyclines, fluconazole, fluoroquinolones, phenolphthalein, acetaminophen, cetirizine, celecoxib, dextromethorphan, hydroxyzine/cetirizine/levocetirizine, quinine, lamotrigine, phenylpropanolamine, erythromycin, metformin, sildenafil, mycophenolate, chemotherapeutic agents, and Chinese and Japanese herbs are also among the long list of possible causes. The risk of developing a FDE has been linked to HLA-B22. Patch tests with various concentrations of the offending medication can reproduce the lesion when placed on affected, but not on unaffected, skin Tape-stripping the skin before applying he suspected medication in various vehicles may increase the likelihood of a positive patch test.
Occasionally, FDEs do not result in long-lasting hyperpigmentation. The so-called nonpigmenting FDE is distinctive and has two variants. The pseudocellulitis or scarlatiniform type is characterized by large, tender, erythematous plaques that resolve completely within weeks, only to recur on reingestion of the offending drug. Pseudoephedrine hydrochloride is by far the most common culprit. The second variant is SDRIFE (formerly baboon syndrome; see “Allergic Contact Dermatitis” earlier). SDRIFE preferentially affects the buttocks, groin, and axillae with erythematous fixed plaques, and is most commonly due to antibiotic agents, particularly aminopenicillins. Histologically, a giant cell lichenoid dermatitis can be seen in this setting. Fixed sunlight eruption has been reported as multiple FDE-like lesions occurring in response to sunlight.
The diagnosis of FDE is often straightforward and is elucidated by the history. Antibiotics manufactured overseas are readily available in many ethnic markets, including reports of such agents as trimethoprim/sulfamethoxazole in over-the-counter cold medications, and the formulations may not be carefully regulated. In some patients, the reaction may be to a dye in a medication rather than the active ingredient. Fixed drug reaction may rarely be related to foods, including residual antibiotics in meat products and quinine contained in tonic water. Confirmation with provocation tests can be performed. Because of the “refractory period,” provocation tests need to be delayed at least 2 weeks from the last eruption. If an oral provocation test is considered, the initial challenge should be 10% of the standard dose, and patients with widespread lesions (SJS/TEN–like) should not be challenged. Patch testing using a drug concentration of 10%–20% in petrolatum or water applied to a previously reacted site is the recommended approach. In most patients, the treatment is simply to stop the medication. Desensitization can be successful.
Lesions of an FDE contain intraepidermal CD8+ T cells with the phenotypic markers of resident memory T cells. Tissue resident memory T cells are thought to remain in the skin to provide immunity to infection (e.g., herpes simplex virus). In FDE, once the medication is stopped, the abundant CD4+/FoxP3 T cells (Tregs) are believed to downregulate the eruption. In SJS/TEN patients, such Tregs are found in much fewer numbers than in FDE, which may explain the progression of SJS/TEN even after stopping the trigger. Resident mast cells in lesions of FDE may be the cells initially activated with drug exposure explaining the rapid onset of the lesion.